Abramson Cancer Center at Penn Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Abramson Cancer Center at Penn Medicine sits in the top decile of US sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count).
Abramson Cancer Center at Penn Medicine: 402 sponsored US clinical trials, 74 recruiting.
Abramson Cancer Center at Penn Medicine sponsors 402 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 235 completed. 3 of these trials are in Phase 3-4 (later-stage) and 175 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 20 trials.
Top-decile sponsor footprint
Abramson Cancer Center at Penn Medicine ranks in the top decile of sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
235 of 280 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
402 total, page 1 of 9
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
NCT07478848
Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)
NCT07454499
Allergy Delabeling in Antibiotic Stewardship - Intervention
NCT07133074
Short Course Radiotherapy
NCT07147179
Comparing Numbing Techniques in Mohs Micrographic Surgery
NCT07222241
A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship
NCT07655934
Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema
NCT06837480
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit
NCT07199517
The Erector Spinae Plane Block For Gastrointestinal Malignancy Pain Treatment (EGIPT)
NCT07211386
Safe and Explainable AI
NCT06694181
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
NCT07278986
FTT PET/CT in Pancreatic Neuroendocrine Tumors
NCT07114939
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
NCT07082439
Vape Use Among Younger & Older Smokers
NCT07214168
Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)
NCT07471958
Telehealth Collaborative Care Model (CoCM) in Lung Cancer
NCT07102147
Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)
NCT06870617
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
NCT06747845
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
NCT06613841
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
NCT06586255
Healthy Volunteers Study
NCT06962059
Hypofractionated WPPT With HDR Boost
NCT06591819
BHB & CAR-T for Lymphomas
NCT06610344
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT06551116
Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers
NCT06372899
Community Support Program for Lung Cancer Screening Volume II
NCT06628167
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
NCT06458439
Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis
NCT06578637
The Role of Flavor in the Substitutability of E-cigarettes for Combustible Cigarettes Among Persistent Smokers
NCT06264154
FAPI-74 PET/CT in Adults With Fibrosis
NCT06413355
Integrating Telehealth to Advance Lung Cancer Screening
NCT06638554
[18F]FES PET/.CT in Uterine Cancer
NCT05916196
Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]
NCT06125743
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES
NCT05968898
Prostate Tissue BioBank
NCT06659614
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT05758688
Assessment of Geriatric Evaluations Impact on New AML Guidance
NCT05909501
FES BPET-DBT in Newly Diagnosed Breast Cancer
NCT05659797
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
NCT05952141
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
NCT04691817
Limited-duration Teclistamab
NCT05932680
QOL and Sarcopenia in Patients With Ascites
NCT05726747
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
NCT05318027
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
NCT05733715
FTT PET/CT in Metastatic Prostate Cancer
NCT05242744
Collection of Circulating Biomarkers in Pancreatic Cancer
NCT05743049
Improve Outcomes for Older Allogeneic Transplant Recipients
NCT05612789
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
NCT05496036
WBSI Guided Personalized Delivery of TTFields
NCT05086497
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
NCT03760575
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 113 |
| Phase 2 | 62 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Abramson Cancer Center at Penn Medicine pipeline
74 recruiting of 402 indexed (18% open); 235 completed (58%).
Phase mix: 3 late (III/IV) vs 175 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abramson Cancer Center at Penn Medicine: open-pipeline peers nationwide
Peers matched on 402 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 402 trials (± recruiting share)
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
Sponsors near 18% open enrollment (± trial volume)
- University of Maryland, Baltimore · 18% recruiting · 560 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this Abramson Cancer Center at Penn Medicine page
402 registered trials is a research-attention snapshot, not an endorsement of Abramson Cancer Center at Penn Medicine or any single study.
- 74 of Abramson Cancer Center at Penn Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Abramson Cancer Center at Penn Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abramson Cancer Center at Penn Medicine pipeline card: 402 registered trials from official public datasets.Report a data error.